Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 7/20 | 0.65 |
| ▸ | DPP4 | P27487 | 3/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197990 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL5201978 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL124005 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL7870187 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL20011747 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL199332 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL25396765 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| SCHEMBL8512122 | 1.00 | HDAC2 (0.65) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| Hydrochloric Acid SCHEMBL18094024 | 0.98 | HDAC2 (0.63) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 | |
| Hydrochloric Acid SCHEMBL10461198 | 0.98 | HDAC2 (0.63) | HDAC2DPP4AKR1C3AKR1C1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| EP-2922559-B1 | SYNTHETIC LINEAR APELIN MIMETICS FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2018-10-10 | — | — | EP | claimed |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | claimed |
| CN-105007928-B | For treating the synthesizing linear APELIN analogies of heart failure | 诺华股份有限公司 | 2018-03-20 | — | — | CN | claimed |
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| US-20160076058-A1 | HYDROCARBON-PRODUCING GENES AND METHODS OF THEIR USE | GENOMATICA, INC. | 2016-03-17 | — | — | US | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | claimed |
| JP-2002506075-A | — | — | 2002-02-26 | — | — | JP | claimed |
| EP-1062222-A1 | SERINE PEPTIDASE MODULATORS | Fondatech Benelux N.V. (BE) | 2000-12-27 | — | — | EP | claimed |
| WO-1999046272-A1 | SERINE PEPTIDASE MODULATORS | FONDATECH BENELUX N.V. (BE) | 1999-09-16 | — | — | WO | claimed |
| EP-0732399-A2 | Chymotrypsin-like proteases and their inhibitors | CEPHALON, INC. (US) | 1996-09-18 | — | — | EP | claimed |
| EP-0518955-A4 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | — | 1993-09-22 | — | — | EP | claimed |
| EP-0518955-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1992-12-23 | — | — | EP | claimed |
| WO-1991013904-A1 | CHYMOTRYPSIN-LIKE PROTEASES AND THEIR INHIBITORS | CEPHALON, INC. (US) | 1991-09-19 | — | — | WO | claimed |
| US-4851514-A | ANGIOTENSIN CONVERTING ENZYME INHIBITOR, REACTING CERIUM TRICHLORIDE WITH PHENYLLITHIUM TO PRODUCE TRIPHENYL CERIUM | E. R. SQUIBB & SONS, INC. (US) | 1989-07-25 | — | — | US | claimed |
| US-4734508-A | GRIGNARD REACTION WITH TRIPHENYLCERIUM | E. R. SQUIBB & SONS, INC. (US) | 1988-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | HDAC2 879/4885DPP4 3/4885AKR1C3 3377/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | HDAC2 4273/4885DPP4 37/4885AKR1C3 2293/4885 |
| US-10005829-B2 | Synthetic linear apelin mimetics for the treatment of heart failure | APLNR, AP3B1, FABP3 | HDAC2 4410/4885DPP4 165/4885AKR1C3 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.